We are a highly collaborative group and our research is founded on strong partnerships with leading investigators, academic groups, patient organizations and pharmaceutical and biotech industry partners within Canada and worldwide.

Local and national collaborations


Kym Boycott is a clinical geneticist at the Children’s Hospital of Eastern Ontario (CHEO), Senior Scientist at the CHEO Research Institute, and Professor of Pediatrics at the University of Ottawa. Kym and Hanns have closely collaborated as founding chairs of the IRDiRC interdisciplinary and diagnostic science committees. They lead on rare disease genomics projects and networks in Europe and Canada.

Bernard Jasmin is Dean and Professor at the Faculty of Medicine, University of Ottawa. His work is focused on cellular and molecular neurobiology with relevance for skeletal muscle and neuromuscular junction disorders. He collaborates with Hanns on myotonic dystrophy and neurophysiology of muscle.

Alex MacKenzie is a principal investigator at the CHEO Research Institute and professor in the Department of Medicine at the University of Ottawa. Alex has made pivotal contributions to molecular discovery, pathophysiology and treatment of several rare childhood disorders, particularly spinal muscular atrophy. Alex and Hanns collaborate on research into biomarkers and treatment of myotonic dystrophy.

Hugh McMillan is Associate Professor of Pediatrics at the University of Ottawa, a pediatric neurologist and neuromuscular specialist at CHEO and a clinical investigator at the CHEO Research Institute. He directs the care of children with neuromuscular disease from a large region of Eastern Ontario and Western Quebec and is principal investigator for several clinical trials in DMD and SMA. Hugh and Hanns collaborate on clinical research for childhood neuromuscular disorders.

Michael Rudnicki is Senior Scientist and Director of the Regenerative Medicine Program and the Sprott Centre for Stem Cell Research at the Ottawa Health Research Institute (OHRI) and Professor in the Department of Medicine and Department of Cellular and Molecular Medicine at the University of Ottawa. He collaborates with Hanns on translational research and regenerative therapies for muscular dystrophies such as Duchenne muscular dystrophy.

Jodi Warman is a Clinician-Scientist in the Department of Medicine at the Ottawa Hospital, Ottawa Hospital Research Institute (OHRI) in Neurosciences and Clinical Epidemiology, and Department of Genetics at the Children’s Hospital of Eastern Ontario/CHEO RI. She is also Assistant Professor and co-Director of the Centre for Neuromuscular Disease at the University of Ottawa. Jodi and Hanns work together clinically on diagnosis and care as well as clinical research for adults with neuromuscular disorders.


Craig Campbell is a scientist at the Division of Children’s Health and Therapeutics, Children’s Health Research Institute and Medical Director, Neuromuscular and Cerebral Palsy Clinics, Thames Valley Children’s Centre in London, Ontario. He has recently become chair of the TREAT-NMD global registries oversight committee. He directs the care of children with neuromuscular disease from a large region of Western Ontario and is principal investigator for several clinical trials in DMD and SMA. Craig and Hanns are long-term collaborators in clinical research and registries for childhood neuromuscular disorders.

Cynthia Gagnon is a professor of rehabilitation medicine at the University of Sherbrooke and has a long-standing research interest in outcome measures and myotonic dystrophy. Cynthia and Hanns collaborate on clinical research for myotonic dystrophy.

Lawrence Korngut is a neurologist and clinical neurophysiologist at the Calgary Neuromuscular Clinic and is the Director of the Calgary ALS and Motor Neuron Disease Clinic. His research includes phase II and III clinical trials of new therapies for neuromuscular conditions. He leads the Canadian Neuromuscular Registry (CNDR) and the Canadian Neuromuscular Network (CAN-NMD). Hanns contributes to the CNDR and CAN-NMD and collaborates with Lawrence on clinical protocols.

International collaborations

Prior to moving to Canada, Hanns was based in Europe (Germany and UK) and has maintained the strong international collaborations he has developed throughout his career. The map below provides a visual representation of our lab’s research and clinical collaborations – click the pins to see the details of each group.


Read next...

Map of Ottawa showing CHEO-RI location

Contact us

Contact us Mailing address: CHEO Research Institute 401 Smyth Road Ottawa, ON K1H 8L1 Canada   Email addresses: See the…

Image of the Ottawa Hospital Civic Campus

Clinical work

Hanns sees neuromuscular patients in clinic at the Neuromuscular Research Centre, located at the Civic Campus of The Ottawa Hospital. This newly opened state-of-the-art centre allows people with NMDs to have consultations with neuromuscular experts and to participate in clinical research.

Rack of newspapers


Read the latest news about our group, our research, our collaborations and our publications here. You can also follow us on Twitter – search for @LochmullerLab.

medicine capsules spilling out of a jar

Industry collaborations

Collaboration with the pharmaceutical industry is essential in order to achieve the translation of preclinical research findings into clinical trials. Hanns is an experienced investigator in commercially sponsored clinical studies and our group also works closely with basic research teams within pharma companies on various preclinical studies.


You can find our most recent publications here – both those coming out of the Lochmüller lab directly and those…

Diseases of interest

Our group is interested in rare inherited neuromuscular diseases, in particular congenital myasthenic syndromes, myotonic dystrophy, GNE myopathy, Duchenne muscular dystrophy and spinal muscular atrophy. We investigate these conditions in the lab and in the clinic in a “bench to bedside” approach.

Researcher using a pipette in a fume hood

Research areas

Although individually uncommon, rare diseases are so numerous that they collectively affect as many as one person in every 17 – in Canada, about 2 million people. Our research program focuses on defining the basic molecular and cellular mechanisms that cause neuromuscular disorders, to enable improved diagnosis, better care and development of effective treatments.

The Lochmuller Lab team

Team members

Find out more about Hanns and his team members here and see whether you would like to join us! We are always interested in hearing from scientists and clinicians at all stages of their careers, whether you want to join the team or start a scientific collaboration.

Hanns's research team in Newcastle, UK

About us

We are a clinical and scientific research team focusing on research into rare neuromuscular disorders and clinical care for patients with these conditions. We aim to understand why small variations in the human genome lead to these frequently disabling, sometimes lethal, and rarely treatable conditions affecting the musculature and nervous system.